DEPO Profile
Depomed, Inc. (DEPO) was a pharmaceutical company that focused on developing and commercializing products for pain and central nervous system (CNS) disorders. The company was founded in 1995 and was headquartered in Newark, California.
Depomed's product portfolio included a range of medications for pain management, including extended-release formulations of opioids and non-opioid analgesics. The company also developed and commercialized medications for CNS disorders, such as epilepsy and migraine headaches.
In 2019, Depomed was acquired by Mallinckrodt Pharmaceuticals, a global specialty pharmaceutical company that focuses on developing and commercializing treatments for rare and severe diseases. The acquisition was aimed at expanding Mallinckrodt's product portfolio and strengthening its position in the pain management and CNS disorders markets.
As a result of the acquisition, Depomed, Inc. is no longer a publicly traded company. However, its legacy continues through its contributions to the development of treatments for pain and CNS disorders, and through the many patients who have benefited from its medications over the years. The acquisition also provided Depomed shareholders with a premium on their investment, and the opportunity to participate in the growth of Mallinckrodt Pharmaceuticals as a leading provider of treatments for rare and severe diseases.
|
